Table 1.
Correlation between Sirt6 expression and clinical characteristics of DLBCL patients
| Characteristics | No. of patients | Sirt6 expression | p value | |
|---|---|---|---|---|
| Negative | Positive (%) | |||
| Age(years) | ||||
| <60 | 41 | 13 | 28(68.3%) | 0.009 |
| ≥ 60 | 29 | 1 | 28(96.6%) | |
| Gender | ||||
| Male | 34 | 6 | 28(82.4%) | 0.858 |
| Female | 36 | 8 | 28(77.8%) | |
| Ann Arbor stage | ||||
| I or II | 35 | 11 | 24(68.6%) | 0.036 |
| III or IV | 35 | 3 | 32(91.4%) | |
| B symptoms | ||||
| Present | 17 | 2 | 15(88.2%) | 0.531 |
| Absent | 53 | 12 | 41(77.4%) | |
| Sybtype | ||||
| GCB | 22 | 6 | 16(72.7%) | 0.479 |
| Non-GCB | 48 | 8 | 40(83.3%) | |
| Serum LDH | ||||
| Normal | 28 | 9 | 19(67.9%) | 0.077 |
| Elevated | 42 | 5 | 37(88.1%) | |
| Extranodal involvement | ||||
| Absent | 14 | 2 | 12(85.7%) | 0.823 |
| Present | 56 | 12 | 44(78.6%) | |
| IPI score | ||||
| 0–2 | 41 | 12 | 29(70.7%) | 0.045 |
| 3–5 | 29 | 2 | 27(93.1%) | |
LDH Lactate dehydrogenase, IPI International prognostic index